---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-23-000003"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:00:18.204845+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q3 FY2023 revenue $7.73B (+4.1% organic), non-GAAP EPS $1.30, raises FY guidance

## Summary
- Revenue $7.727B flat as reported, +4.1% organic; GAAP EPS $0.92 (-16%), non-GAAP EPS $1.30 (-4%), both ahead of expectations.
- Cardiovascular +7% organic, Neuroscience +7% organic; Medical Surgical -2% organic (ex-ventilator/China +3%).
- FY2023 non-GAAP EPS guidance raised to $5.28-$5.30 from $5.25-$5.30; Q4 organic revenue growth expected 4.5-5.0%.
- Planned separations: Respiratory/Patient Monitoring (H2 FY2024) and Renal Care Solutions with DaVita (Q4 FY2023).

## SEC filing metadata
- accession: 0001613103-23-000003
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310323000003/0001613103-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310323000003/mdt-20230221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-23-000003
- JSON: https://secwatch.observer/filing/0001613103-23-000003.json
- Plain text: https://secwatch.observer/filing/0001613103-23-000003.txt

## Key facts
- Earnings Releases
  Medtronic plc reported third quarter fiscal year 2023 ended January 27, 2023 results: revenue $7.727 billion, net income $1.222 billion (GAAP); $1.727 billion (non-GAAP), EPS $0.92 (GAAP diluted); $1.30 (non-GAAP diluted). Guidance raised.
  - Period: third quarter fiscal year 2023 ended January 27, 2023
  - Revenue: $7.727 billion
  - Net income: $1.222 billion (GAAP); $1.727 billion (non-GAAP)
  - EPS: $0.92 (GAAP diluted); $1.30 (non-GAAP diluted)
  - Guidance: raised
  - Result: reported results
  source text: Medtronic reports third quarter fiscal 2023 financial results Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios DUBLIN – Feb. 21, 2023 – Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2023, which ended January 27, 2023. Key Highlights • Revenue of $7.7 billion was flat as reported and increased 4.1% organic, ahead of expectations • GAAP diluted EPS of $0.92 decreased 16%; non-GAAP diluted EPS of $1.30 decreased 4%, ahead of expectations • Company increases FY23 organic revenue growth and EPS outlook
  evidence_url: https://www.sec.gov/Archives/edgar/data/1613103/000161310323000003/0001613103-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.